Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01027260
Recruitment Status : Completed
First Posted : December 7, 2009
Last Update Posted : June 18, 2013
Information provided by (Responsible Party):

Brief Summary:
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Drug: Itopride HCI 50 mg Drug: Itopride HCI 100 mg Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 268 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled Study on the Efficacy of Itopride HCI on Irritable Bowel in Patients of Irritable Bowel Syndrome With Constipation (IBS-C)
Study Start Date : June 2008
Actual Primary Completion Date : August 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Itopride 50 mg Drug: Itopride HCI 50 mg
Variable dosing
Other Names:
  • ABT-654
  • Itopride HCI
  • Ganaton
Active Comparator: Itopride 100 mg Drug: Itopride HCI 100 mg
Variable dosing
Other Names:
  • ABT-654
  • Itopride HCI
  • Ganaton
Placebo Comparator: Placebo Drug: Placebo
Variable dosing

Primary Outcome Measures :
  1. Patients will be asked a simple but well validated question "If there is a satisfactory relief of the symptoms" [ Time Frame: 2 weeks and 4 weeks after the start of the treatment ]

Secondary Outcome Measures :
  1. Subjects will be assessed based on Irritable Bowel Syndrome Severity Score (IBSSS). [ Time Frame: 2 weeks and 4 weeks after the start of the treatment ]
  2. Safety based on the laboratory tests before and at the end of the treatment. [ Time Frame: 4 weeks during the treatment period and 4 weeks following post- therapy period. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patient fulfilling the Rome III criteria for IBS-C
  2. Signed informed consent at screening visit

Exclusion Criteria:

  1. Patients having significant diarrhea at least 25% of the time during the past 3 months
  2. Patients having alarm symptoms or signs
  3. Chronic diarrhea
  4. History of gastrointestinal haemorrhage, mechanical obstruction or perforation
  5. Patient with clinically relevant ECG abnormalities (prolonged QT interval)
  6. Active psychiatric disorder that would interfere with the study objectives
  7. Health conditions (e.g. age related impairment of cognitive functions) that would interfere with the study objectives or might impair the compliance of the patient
  8. Severe hepatic, renal, cardiac, metabolic, haematological or malignant diseases (including prolactin dependent tumours) or clinically relevant deviations in laboratory values (AST/ALT greater than twice the upper limit of normal, serum creatinine * 2 mg/dl [177 µmol/l] according to the medical judgement of the investigator
  9. Patient with hypokalemia (serum potassium < 3.5 mmol/l).
  10. History of any known hypersensitivity to the ingredients of the investigational drug
  11. Pregnancy or lactation
  12. Women with childbearing potential who do not apply a medically accepted method of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01027260

Site Reference ID/Investigator# 5870
Karachi, Pakistan, 74800
Site Reference ID/Investigator# 21441
Karachi, Pakistan
Site Reference ID/Investigator# 6130
Lahore, Pakistan
Site Reference ID/Investigator# 8535
Rawalpindi, Pakistan
Sponsors and Collaborators

Responsible Party: Abbott Identifier: NCT01027260     History of Changes
Other Study ID Numbers: R10-257
First Posted: December 7, 2009    Key Record Dates
Last Update Posted: June 18, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases